| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 06/03/2025 | 22:02 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 24/02/2025 | 22:01 | Business Wire | Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 14/02/2025 | 14:30 | PR Newswire (US) | European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 14/02/2025 | 14:00 | Business Wire | European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 04/02/2025 | 14:30 | Business Wire | Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 31/01/2025 | 09:00 | Business Wire | Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19 | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 30/01/2025 | 22:01 | Business Wire | Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 10/01/2025 | 14:00 | Business Wire | Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 06/01/2025 | 22:01 | Business Wire | Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 18/12/2024 | 22:07 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 16/12/2024 | 22:01 | Business Wire | Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 26/11/2024 | 22:01 | Business Wire | Arcturus Therapeutics to Attend Upcoming Investor Conferences | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 19/11/2024 | 02:00 | Business Wire | Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 14/11/2024 | 07:00 | Business Wire | Meiji Seika Pharma Announces Investment in ARCALIS, Inc. | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 11/11/2024 | 22:01 | Business Wire | Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 07/11/2024 | 22:01 | Business Wire | Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 31/10/2024 | 21:01 | Business Wire | Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 30/09/2024 | 14:00 | PR Newswire (US) | Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 13/09/2024 | 14:15 | PR Newswire (US) | Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 13/09/2024 | 14:00 | Business Wire | Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 03/09/2024 | 14:30 | Business Wire | Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 27/08/2024 | 23:00 | Business Wire | Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 05/08/2024 | 22:50 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 05/08/2024 | 22:01 | Business Wire | Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 01/08/2024 | 22:01 | Business Wire | Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 19/07/2024 | 01:30 | Business Wire | Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024 | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 17/07/2024 | 23:27 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 01/07/2024 | 22:01 | Business Wire | Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 20/06/2024 | 14:00 | Business Wire | Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
| 07/06/2024 | 16:30 | Business Wire | Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference | NASDAQ:ARCT | Arcturus Therapeutics Holdings Inc |
